ESSA Pharma Inc
NASDAQ:EPIX
ESSA Pharma Inc
Operating Income
ESSA Pharma Inc
Operating Income Peer Comparison
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
ESSA Pharma Inc
NASDAQ:EPIX
|
Operating Income
$-31.9m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
N/A
|
|
Zymeworks Inc
NYSE:ZYME
|
Operating Income
$-138.1m
|
CAGR 3-Years
10%
|
CAGR 5-Years
-33%
|
CAGR 10-Years
N/A
|
|
Theratechnologies Inc
TSX:TH
|
Operating Income
$-19m
|
CAGR 3-Years
0%
|
CAGR 5-Years
-28%
|
CAGR 10-Years
-15%
|
|
Repare Therapeutics Inc
NASDAQ:RPTX
|
Operating Income
$-116.2m
|
CAGR 3-Years
-30%
|
CAGR 5-Years
-55%
|
CAGR 10-Years
N/A
|
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
Operating Income
$-91.7m
|
CAGR 3-Years
4%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-36%
|
|
Spectral Medical Inc
TSX:EDT
|
Operating Income
CA$-8.2m
|
CAGR 3-Years
1%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
2%
|
See Also
What is ESSA Pharma Inc's Operating Income?
Operating Income
-31.9m
USD
Based on the financial report for Dec 31, 2023, ESSA Pharma Inc's Operating Income amounts to -31.9m USD.
What is ESSA Pharma Inc's Operating Income growth rate?
Operating Income CAGR 5Y
-23%
Over the last year, the Operating Income growth was 11%. The average annual Operating Income growth rates for ESSA Pharma Inc have been -7% over the past three years , -23% over the past five years .